Immune checkpoint inhibitors (ICIs), particularly antibodies targeting programmed cell death protein 1 (PD-1) and its ligand PD-L1, have revolutionized cancer treatment by restoring T cell-mediated antitumor immunity [1,2,3]. Here, PDCD1 is linked to cancer.